Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison

BMC Public Health

Volumn 6, Issue , 2006, Pages

  Sutton, Andrew J ^a,b   Edmunds, W John ^a   Gill, O Noel ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; HEALTH PRACTITIONER; HEPATITIS C; HUMAN; POLYMERASE CHAIN REACTION; PRISON; RECEPTIVE FIELD; SCREENING TEST; ADULT; BLOODBORNE BACTERIUM; COMPLICATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEPATITIS C, CHRONIC; MASS SCREENING; MIDDLE AGED; PRISONER; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; UNITED KINGDOM;

ADULT; BLOOD-BORNE PATHOGENS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ENGLAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS C, CHRONIC; HUMANS; MASS SCREENING; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRISONERS; PRISONS; RISK ASSESSMENT; SUBSTANCE ABUSE, INTRAVENOUS; WALES;

EID: 33747400577     PISSN: 14712458     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-6-170     Document Type: Article

References (26)

1. Limburg W: Natural history, treatment and prevention of hepatitis C in injecting drug users; an overview. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. Lisbon, European Monitoring Centre for Drugs and Drug Addiction; 2004:21-38.
2. www.hpa.org.uk. Website 2006.
3. Leal P, Stein K, Rosenberg W: What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen 1999, 6:124-131.
4. Agency HP, Scotland HP, National Public Health Service for Wales, Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting drug users in the United Kingdom 2004, An update: October 2005 London, Health Protection Agency; 2005.
5. Weissing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll R: Surveillance of hepatitis C infection among injecting drug users in the European Union. In Hepatitis C and injecting drug use: impact, costs and policy options Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. Luxembourg, European Monitoring Centre for Drugs and Drug Addiction; 2006:91-135.
6. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002, 129:577-585.
7. de Angelis D, Hickman M, Yang S: Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004, 160:994-1004.
8. Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L: A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction 2001, 96:1465-1476.
9. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003, 52:1500-1504.
10. Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G: Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci 2003, 16:99-106.
11. Reuter P: What drug policies cost: estimating government drug policy expenditures. Addiction 2006, 101:315-322.
12. Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL, Piper M, Gill ON: Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect 2006, 134:231-242.
13. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M: Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006, 6:93.
14. Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD: Hepatitis C infection and incarcerated populations. The International Journal of Drug Policy 2004, 151:103-114.
15. Health Protection Agency Centre for Infections: Hepatitis C in England: The First Health Protection Agency Annual Report. London; 2005.
16. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ 1999, 319:290-291.
17. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998, 51:253-263.
18. Treasury HM: The Green Book, Apprasial and Evaluation in Central Government 2003.
19. Mortimer P: Ready, steady, go for HCV antigen testing? Commun Dis Public Health 2000, 3:154-155.
20. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47:1-39.
21. Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME: Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf) 2004, 26:372-375.
22. Guidance on the use of Ribavirin and Interferon Alpha for Hepatitis C. Volume 14. National Institute for Clinical Excellence; 2000.
23. Curtis L, Netten A: Unit Costs of Health and Social Care Personal Social Services Research Unit; 2004.
24. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002, 6(31):1-122.
25. www.hpa.org.uk. Website 2005.
26. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.